Cancer

  • About the area
  • Groups

The area of ​​cancer research has been structured into three different pillars: clinical research, translational laboratory research and innovation in cancer diagnosis and treatment.

Within the clinic, we can currently find four lines of research that have to do with the volume of incidence and prevalence of neoplastic disease, such as: breast cancer, lung cancer, urological tumors and gastrointestinal tumors. Each of them is made up of professionals who are dedicated to the diagnosis, treatment and follow-up of specific neoplasms.

In all lines there is extensive experience in conducting national and international studies. Many of the members belong to different national and international scientific societies, which allows them to be in touch with the latest scientific advances. Work is currently underway to increase the specific number of clinical research lines.

Within translational research, the goal has been set in the study at the cellular and molecular level of cancer with particular interest in the identification of new biomarkers that allow us to predict the survival of our cancer patients in their different types and stages, as well as adapting the treatment in a more personalized way. Work is also underway to increase cooperation with all those professionals who are researching into some type of cancer.

Finally, the cancer innovation group is investigating several strategic lines for the development of new diagnostic and treatment tools using new technologies with potential application in health.

Strategic lines of the area

  • Research into new oncological therapies.
  • Study of biomarkers involved in the prognosis and prediction of the effectiveness of oncological treatments.
  • Search for new diagnostic tools based on artificial intelligence.
Area coordination
Miquel Àngel Seguí

msegui@tauli.cat

Group A1G4 - Biomedical research in cancer

Accreditation level: Consolidated group

The incidence of cancer is gradually increasing worldwide, as well as being one of the leading causes of death in our environment. The importance of having new knowledge about the behavior of the disease is a challenge of obvious relevance.

The Biomedical Research in Cancer group is a group with a long clinical research history. It is made up of professionals from different medical and surgical specialties, which allows us to tackle cancer research in a multidisciplinary and global way, addressing the prognostic, clinical and molecular factors of cancer, as well as developing new treatment options. Specifically, the group is working on the study of new drugs and therapies for breast, ovarian, head and neck, lung, digestive, and thyroid cancers.

The group participates with national and international companies and groups, such as SEOM, GEICAM, SOGUG, TTD, GEMCAD and EORTC, which allows the development of projects in a wide field with which results are achieved with a high degree of evidence.

Lines of research

  • Research into new drugs and effective therapies in cancer patients.
  • Study of biomarkers involved in the prognosis and prediction of treatment efficacy.
  • Search for supportive treatment for cancer patients: palliative care and improvement of treatment side effects.
  • Oncogeriatric assessment tools. Definition and evaluation of its effectiveness and its impact on patients' quality of life.

Composition of the group

Enrique Gallardo Diaz (Cap de grup)

Doctoral research staff

  • Bejarano González, Natalia
  • Fernández Morales, Luís Antonio
  • Garcia Borobia, Francisco Javier
  • Garcia Monforte, Neus
  • Guirao Garriga, Francisco Javier
  • Pericay Pijaume, Carles
  • Seguí Palmer, Miquel Àngel
  • Muñoz Rodríguez, Jesús

Predoctoral

  • Castañer González, Eva
  • Dalmau Pórtulas Elsa
  • Domínguez García, Arturo
  • Garcia Garcia, Yolanda
  • García Rojo, Darío
  • Hannaoui Hadi, Naim
  • Macias Declara, Ismael
  • Medarde Ferrer, Meritxell
  • Morales Quintero, Luis

Non-doctoral research staff

  • Aparicio Rodríguez, Óscar
  • Bonfill Abella, Teresa
  • List Arias, Eva
  • López Mestres, Aida
  • Llort Pursals, Gemma
  • Medina Argení, Sandra
  • Nogales Herranz, Sara
  • Pleasures Gago, Angeles
  • Ribera Fernández, Paula
  • Ribot Luna, Laia
  • Rodríguez Castells, Marta
  • Vila Martínez, Laia
  • Yébenes Marsal, Mireia

Associated professionals

  • Andreu Magarolas, Marta
  • Barcons Vilaplana, Santi
  • Cabrera Romero, José Manuel
  • Gallardo Cistaré, Xavier
  • Giner Joaquin, Júlia
  • Malet Munté, Antoni
  • Nogueiras Pérez, Rosa
  • Pérez Riverola, Víctor
  • Prenafeta Moreno, Mario
  • Puig Domingo, Jordi
  • Ribot Berenguer, Teresa

Group A1G5 - Molecular and Translational Research in Cancer

Accreditation level: Popup group 

2017 SGR 473

The Molecular and Translational Research Group on Cancer carries out several projects aimed at research at the cellular and molecular level of cancer with particular interest in the search for biomarkers for the diagnosis, prognosis and prediction of response to treatment.

The aim is that the results of this research can be transferred to clinical practice and be able to offer cancer patients a more personalized and appropriate treatment for each type of tumor.

The group is made up of postdoctoral and predoctoral researchers, mostly from the pathology department of our Hospital. It also has close internal and external collaborations with researchers from various prestigious groups, which allows a multidisciplinary approach to research projects.

Lines of research

  • Clinicopathological and molecular characterization of thyroid cancer.
  • Research into new biomarkers for the diagnosis and prognosis of colon cancer.
  • Research in the genomics of lung cancer.
  • Clinicopathological and molecular characterization of endometrial and ovarian carcinoma.

Composition of the group

Anna Brunet Vega (Group leader)

Doctoral research staff

  • Bella Cueto, M. Rosa
  • Costa Trachsel, Irmgard
  • Ferreres Piñas. Joan Carles

Predoctoral

  • Blázquez Maña, Carmen María
  • Carrera Salas, Ruben
  • Papaleo, Natalia
  • Reques Llanos, Armando

Associated professionals

  • Casalots Casado, Alex
  • Escoda Giral, Rosa
  • Sáez Artacho, Empar

A1G6 Group - Innovation in Cancer

Accreditation level: Popup group

The cancer innovation group is made up of different lines of basic research whose general objectives are to improve current diagnostic tests to make them more reliable and predictable, as well as to investigate potential new treatments that are less invasive than current ones. cancers with worse prognosis.

We aim for all the innovative results obtained in the laboratory to move to the clinical phase in the shortest possible time, always thinking about the positive impact that this would have in the healthcare field, and obviously in patients. For this reason, we focus our research on:

  • Use innovative cellular (3D) models that allow us to obtain more accurate results than conventional models, while reducing animal experimentation.
  • Develop new potentially curative treatments based on state-of-the-art technologies that make therapies more accurate and safe.
  • Improve current brain tumor diagnostic techniques using: i) artificial intelligence (AI) in medical imaging techniques, and ii) peripheral blood liquid biopsy.
  • Perform Monte Carlo simulations to predict and optimize the effects of radio-oncological treatments.

All this is possible thanks to the collaborations, both internal and external, that we have established with other prestigious groups (ALBA, ICN2, UAB, UB, Hospital Clínic, Eurecat?), And that allow us to create the necessary synergies for continue to grow innovation in the field of cancer research.

Lines of research

  • Investigation of the role of technological innovation in both the diagnosis and treatment of neoplasms in diagnostic support (IA) and in new non-pharmacological treatments.
  • Exploration of more realistic (and comparable to neoplasm) cell cultures, which take into account cell-cell and cell-microenvironment interactions.
  • Study of magnetic hyperthermia for the treatment of resistant tumors.

Composition of the group

Silvia Gil Duran (Group leader)

Doctoral research staff

  • Bernà Roqueta, Lluís
  • Caresia Aroztegui, Paula
  • Moragas Solanes, Mercedes

Non-doctoral research staff

  • Del Riego Ferrari, Javier
  • Estela Herrero, Jordi
  • Martín Olóriz, Amaya

Associated professionals

  • Codina Aroztegui, Clara
  • Escribano Alcántara, Fernanda
  • Martin Miramon, Joan Carles
  • Tortajada Giménez, Lidia
  • Villajos Fernández, María Teresa
Privacy preferences

When you visit our website, your browser may store information about specific services, usually in the form of cookies. Here you can change your privacy preferences. Please note that blocking certain types of cookies may affect your experience on our website and the services we offer.

Enable / disable Google Analytics tracking code
Enable / disable Google Fonts
Turn Google Maps on / off
Enable / disable embedded videos
This website uses cookies, mainly from third party services. You can edit your privacy preferences and / or accept the use of cookies.